Beranda › Kanker Paru › Vermont › Burlington
Uji klinis Kanker Paru di Burlington, VT
4 studi untuk Kanker Paru mencari peserta di lokasi sekitar Burlington (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Menerima pesertaFase 3
- The University of Vermont Medical Center Inc., Burlington
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- University of Vermont Medical Center, Burlington
- University of Vermont and State Agricultural College, Burlington
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- University of Vermont Medical Center, Burlington
- University of Vermont and State Agricultural College, Burlington
Accelerated Pulmonary Rehabilitation in the Preoperative Period
Menerima peserta
- University of Vermont Medical Center, Burlington
Uji klinis Kanker Paru di kota lain
- Houston, TX78 studi
- Boston, MA62 studi
- New York City, NY60 studi
- Los Angeles, CA45 studi
- Arlington, VA41 studi
- Washington, DC41 studi
- Chicago, IL41 studi
- Baltimore, MD40 studi
- Nashville, TN40 studi
- St. Louis, MO39 studi
- Columbus, OH37 studi
- Philadelphia, PA36 studi
Studi lain di Burlington
- Gagal Jantung8 studi
- Leukemia Mieloid Akut7 studi
- Kanker (semua jenis)6 studi
- PPOK5 studi
- Kanker Payudara5 studi
- Leukemia4 studi
- Penyakit Parkinson4 studi
- Penyakit Kardiovaskular4 studi
- Fibrosis Kistik4 studi
- Kanker Paru Non-Sel Kecil4 studi
- Kanker Prostat4 studi
- Kanker Metastatik4 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.